Pharmaceuticals News and Research

RSS

Senate votes to reject Medicare cuts; Reid discusses next anticipated amendments

The Associated Press reported: "Senators voted 58-42 to reject an amendment by Republican Sen. John McCain of Arizona that would have stripped more than $400 billion in Medicare cuts from the health care bill. The measure would have sent the bill back to the Senate Finance Committee for a redo" (Alonso-Zaldivar, 12/3).

4 Dec 2009

Report on the type 2 diabetes drug market in Brazil

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.

3 Dec 2009

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

3 Dec 2009

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

Shire plc, the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot of the Attention-Deficit/Hyperactivity Disorder (ADHD) patch Daytrana®. Shire is taking this action because some Daytrana patches do not meet or in the future may not meet their release liner removal specification, and as a result, patients and caregivers could have difficulty removing the liners.

3 Dec 2009

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

Amira Pharmaceuticals, Inc. announced today initial positive data from a Phase 1 clinical study of AM461, the Company's second oral selective antagonist of the DP2 (also known as CRTH2) receptor.

3 Dec 2009

Enzon Pharmaceuticals announces share repurchase program

Enzon Pharmaceuticals, Inc. announced today that its Board of Directors has authorized the repurchase of up to $50 million of its outstanding shares of common stock in order to return value to its shareholders.

3 Dec 2009

Milestone Scientific announces new joint venture with two PRC pharmaceutical companies

Milestone Scientific Inc., the recognized leader in advanced injection technologies, today announced that it had entered into a joint venture with China National Medicines Corporation Ltd. (d/b/a "Sinopharm") and Yichang Humanwell Pharmaceutical Co. Ltd., both incorporated in the People's Republic of China (the "PRC"), to develop orthopedic and epidural drug delivery instruments.

3 Dec 2009

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

Endo Pharmaceuticals today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its extended-duration testosterone undecanoate injection, AVEED(TM), for men diagnosed with low testosterone.

3 Dec 2009

FDA approves manufacture of Amneal Pharmaceuticals' Nizatidine Oral Solution

Amneal Pharmaceuticals is pleased to announce that it has received U.S. FDA approval to manufacture Nizatidine Oral Solution in the 15 mg/mL strength effective November 18, 2009. It is an AA-rated, therapeutically equivalent alternative to Axid® Oral Solution (a licensed trademark of Braintree Labs). Nizatidine Oral Solution is the first available generic in oral solution form and marks Amneal’s fourth liquid approval.

3 Dec 2009

CBO report shows hundreds of millions spent on direct marketing of drugs to consumers

The Congressional Budget Office released an "interesting report" on on how "pharmaceutical companies market prescription drugs, a subject that has received some scrutiny during the debate on ways to control health care spending," The New York Times reports.

3 Dec 2009

Enrollment closed early in Cubist Pharmaceuticals' ecallantide Phase 2 program

Cubist Pharmaceuticals, Inc. today announced the early closing of enrollment in its ecallantide Phase 2 program. Ecallantide, in development as therapy to reduce bleeding in on-pump cardiac surgery, is now known as CB-500,929. After a regularly scheduled review meeting, the Data Safety Monitoring Board (DSMB) contacted the company to recommend a temporary suspension in enrollment in one of the CB-500,929 trials, CONSERV-2.

3 Dec 2009

Global HIV reporting and monitoring system provides good indication of overall progress towards HIV goal

Although much work remains to be done, a United Nations global reporting system on HIV/AIDS has already yielded an "unequaled wealth of data" on progress toward meeting UN targets for responding to the global HIV epidemic.

3 Dec 2009

China's SFDA initiates quality investigation of Simcere Pharmaceutical Group subsidiary's rabies vaccine

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported that China's State Food and Drug Administration ("SFDA") has initiated a comprehensive investigation into quality issues regarding human use rabies vaccine (vero cell) manufactured by Simcere's subsidiary Jiangsu Yanshen Biological Technology Stock Co., Ltd. ("Jiangsu Yanshen").

3 Dec 2009

NOXXON Pharma achieves important milestone in drug discovery

NOXXON Pharma AG (NOXXON), the biopharmaceutical company focusing on the development of novel medicines based on its unique proprietary Spiegelmer® technology, announced today the achievement of an important milestone in its drug discovery and development partnership with Eli Lilly and Company.

3 Dec 2009

PEG polymer may prevent GI injury during cancer radiotherapy

A non-absorbed, oral co-polymer therapy under development by Midway Pharmaceuticals demonstrated the ability to protect against damage to healthy gastrointestinal tissues and to prevent lethal bacterial infections in animal models of radiation damage.

3 Dec 2009

AACR offers a compendium of best research practices to aid the FDA in regulating tobacco

When President Barack Obama signed the Family Smoking Prevention and Control Act in June, he ushered in a new era of tobacco policy that empowers the Food and Drug Administration to regulate one of the world's most controversial and deadly consumer products.

3 Dec 2009

Medical research experts explore new strategies to speed up treatments for medical disorders

Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugural Partnering for Cures meeting.

3 Dec 2009

New study suggests e-cigarettes can help alleviate nicotine cravings and improve general health

A groundbreaking new survey into the electronic cigarette, smokers' health and smoking cessation, carried out by NJOY retailers E Cigarette Direct and analysed by tobacco harm reduction scientists, has shown encouraging results.

3 Dec 2009

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

arGEN-X BV, a biopharmaceutical company focused on the discovery and development of human antibodies using its proprietary SIMPLE Antibody(TM) platform, today announced the successful second closing of its Series A equity financing round. The Company raised an additional EUR 3.0 million (~USD 4.5 million) from two leading life science investors, Credit Agricole Private Equity and VIB (the prestigious Flemish research institute).

3 Dec 2009

Vertex Pharmaceuticals signs agreement to sell common stock shares

Vertex Pharmaceuticals Incorporated today announced that it has entered into an agreement to sell 11,500,000 shares of its common stock in an underwritten offering at a price to the public of $38.50 per share, which would result in aggregate gross proceeds of $442.8 million.

3 Dec 2009

Pharmaceuticals News and Research

Senate votes to reject Medicare cuts; Reid discusses next anticipated amendments

Report on the type 2 diabetes drug market in Brazil

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

Shire voluntarily recalls specific lots of its Daytrana ADHD patches

Initial positive data from Amira Pharmaceuticals' Phase 1 clinical study of AM461 DP2 antagonist

Enzon Pharmaceuticals announces share repurchase program

Milestone Scientific announces new joint venture with two PRC pharmaceutical companies

Endo Pharmaceuticals receives FDA complete response letter for AVEED NDA

FDA approves manufacture of Amneal Pharmaceuticals' Nizatidine Oral Solution

CBO report shows hundreds of millions spent on direct marketing of drugs to consumers

Enrollment closed early in Cubist Pharmaceuticals' ecallantide Phase 2 program

Global HIV reporting and monitoring system provides good indication of overall progress towards HIV goal

China's SFDA initiates quality investigation of Simcere Pharmaceutical Group subsidiary's rabies vaccine

NOXXON Pharma achieves important milestone in drug discovery

PEG polymer may prevent GI injury during cancer radiotherapy

AACR offers a compendium of best research practices to aid the FDA in regulating tobacco

Medical research experts explore new strategies to speed up treatments for medical disorders

New study suggests e-cigarettes can help alleviate nicotine cravings and improve general health

arGEN-X to develop its SIMPLE Antibody engine with completed EUR 12.5M Series A equity financing

Vertex Pharmaceuticals signs agreement to sell common stock shares

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence